141 related articles for article (PubMed ID: 37213608)
1. Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status?
Xia Y; Chen Y; Chen J; Gan Y; Su C; Zhang H; Long E; Yan F; Yang Y
Front Public Health; 2023; 11():1090623. PubMed ID: 37213608
[TBL] [Abstract][Full Text] [Related]
2. Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China.
Yang Y; Xia Y; Su C; Chen J; Long E; Zhang H; Gan Y; Yan F; Chen Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4205-4214. PubMed ID: 36056953
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China.
Yang K; Hua S; Wei W; Yang C; Zhu X; Li SC
J Med Econ; 2023; 26(1):1424-1431. PubMed ID: 37855437
[TBL] [Abstract][Full Text] [Related]
4. Does caring for patients with advanced non-small cell lung cancer affect health-related quality of life of caregivers? A multicenter, cross-sectional study.
Yang Y; Liu L; Chen J; Gan Y; Su C; Zhang H; Long E; Yan F; Chen Y
BMC Public Health; 2024 Jan; 24(1):224. PubMed ID: 38238722
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
7. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
8. The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers.
Wood R; Taylor-Stokes G; Lees M
Support Care Cancer; 2019 May; 27(5):1709-1719. PubMed ID: 30121787
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life and its influencing factors for patients with hypertension: evidence from the urban and rural areas of Shaanxi Province, China.
Zhang Y; Zhou Z; Gao J; Wang D; Zhang Q; Zhou Z; Su M; Li D
BMC Health Serv Res; 2016 Jul; 16():277. PubMed ID: 27430314
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Shao T; Ren Y; Zhao M; Tang W
Front Public Health; 2022; 10():912921. PubMed ID: 36045725
[TBL] [Abstract][Full Text] [Related]
11. Health state utilities in patients with advanced non-small-cell lung cancer in China.
Shen Y; Wu B; Wang X; Zhu J
J Comp Eff Res; 2018 May; 7(5):443-452. PubMed ID: 29775084
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of 274 non-small cell lung cancer patients in China.
Chen Y; Han S; Zheng MJ; Xue Y; Liu WC
Onkologie; 2013; 36(5):248-54. PubMed ID: 23689218
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
14. [Survey of economic burden of hepatitis B-related diseases in 12 areas in China].
Ma QS; Liang S; Xiao HW; Zhang SX; Zhuang GH; Zou YH; Tan HZ; Liu JC; Zhang YH; Xu AQ; Zhang L; Feng XX; Hu DS; Wang FZ; Cui FQ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):868-876. PubMed ID: 28738457
[No Abstract] [Full Text] [Related]
15. The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
Zeng X; Karnon J; Wang S; Wu B; Wan X; Peng L
PLoS One; 2012; 7(10):e48323. PubMed ID: 23118985
[TBL] [Abstract][Full Text] [Related]
16. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
Reck M; Taylor F; Penrod JR; DeRosa M; Morrissey L; Dastani H; Orsini L; Gralla RJ
J Thorac Oncol; 2018 Feb; 13(2):194-204. PubMed ID: 29129758
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden for Lung Cancer Survivors in Urban China.
Zhang X; Liu S; Liu Y; Du J; Fu W; Zhao X; Huang W; Zhao X; Liu G; Mao Z; Hu TW
Int J Environ Res Public Health; 2017 Mar; 14(3):. PubMed ID: 28294998
[TBL] [Abstract][Full Text] [Related]
18. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
De Castro J; Insa A; Collado-Borrell R; Escudero-Vilaplana V; MartÃnez A; Fernandez E; Sullivan I; Arrabal N; Carcedo D; Manzaneque A
BMC Pulm Med; 2023 Feb; 23(1):69. PubMed ID: 36809990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
